替格瑞洛临床应用中国专家共识

发布时间：2018-04-05 18:23

  本文选题：替格瑞洛　切入点：冠心病　出处：《临床军医杂志》2016年05期

【摘要】：正冠心病是一种猝死率高、危害严重的常见疾病,规范冠心病管理是改善预后、降低死亡率的关键,无论采取药物或介入治疗,抗血小板治疗均是冠心病管理的基石。双联抗血小板,即阿司匹林联合一种P2Y_(12)受体拮抗剂是急性冠状动脉综合征(acute coronary syndromes,ACS)和(或)经皮冠状动脉介入(percutaneous coronary intervention,PCI)患者的标准治疗。替格瑞洛是一种新型强效
[Abstract]:Positive coronary heart disease is a common disease with high sudden death rate and serious harm. Standardized management of coronary heart disease is the key to improve prognosis and reduce mortality. Antiplatelet therapy is the cornerstone of coronary heart disease management no matter taking drugs or interventional therapy.Dual antiplatelet, or aspirin combined with a P2YS-1 receptor antagonist, is the standard treatment for patients with acute coronary syndrome (ACS) and / or percutaneous coronary intervention (coronary interventionn).Tigrilo is a new type of strong effect.
【作者单位】： 中国医师协会心血管内科医师分会血栓防治专业委员会;中华医学会心血管病分会介入学组;中华心血管病杂志编辑委员会;
【分类号】：R972
，

本文编号：1715927